17 Apr 2008 | 09:35
HSBC MF declares dividend
HSBC Mutual Fund has announced 22 April 2008 as the record date for declaration of dividend under dividend option of HSBC Fixed Term Series 22-regular plan. The fund house has decided to distribute 100% of surplus available as on record date. The NAV for the scheme was Rs. 10.0642 as on 15 April 2008.
HSBC Fixed Term Series 22 is a close-ended income scheme seeks to generate reasonable returns by investing in a portfolio of fixed income instruments normally maturing in line with the time profile of the pan.
The scheme will charge 2% exit load if investment units redeemed before maturity.
17 Apr 2008 | 09:56
SBI MF declares dividend
The SBI mutual fund has announced the declaration of dividend under dividend option of SBI Debt Fund Series-15 Months-2. The record date for dividend will be 22 April 2008.
The quantum of dividend is 100% of surplus available as on record date. The NAV of the scheme was recorded at Rs 10.3792 as on 9 April 2008.
SBI Debt Fund Series-15 Months-2 was launched in January 2007. It is a close-ended debt scheme, with an objective to provide regular income, liquidity and returns to the investors through investments in a portfolio comprising of debt instruments such as government securities, AAA/AA+ bonds and money market instruments.
17 Apr 2008 | 10:06
JP Morgan AMC appoints new Fund managers
JP Morgan Asset Management Company has appointed Fund Managers for the following schemes:
JP Morgan India Equity Fund and JP Morgan India Smaller Companies Fund:
Mr Harshd Patwardhan and Mr Amit Gadgil for equity Mr Nandkumar Surti and Mr Namdev Chougule for debt.
JP Morgan India Liquid Fund and JP Morgan India Liquid Plus Fund:
Mr Nandkumar Surti and Mr Namdev Chougule
The aforesaid changes are proposed to be done with effect from 17 April 2008.
17 Apr 2008 | 10:16
Franklin Templeton MF changes name of its Pharma Fund
Franklin Templeton mutual fund has changed the name of Franklin Pharma Fund from ET Lifex to ET Pharma. The changes are to be effective from 15 April 2008. The scheme is an open-ended growth scheme with an objective to provide long-term capital appreciation from a portfolio that is invested in shares of companies operating in pharmaceutical/ life science industry sector.
All the other terms and conditions of the scheme will remain unchanged.
